MSACL 2019 US Abstract

Analytical Strategies to Study the Interaction Between Microbiota and Drug Metabolism using Targeted and Untargeted LC-MS-based Metabolomics

Marine Letertre1, Nyasha C. Munjoma2, Adele Costabile3, Lesley Hoyles1, Aadra Bhatt4, Anne L. McCartney5, Muireann Coen6, Matthew Redinbo4, Jeremy K. Nicholson1, Jonathan R. Swann1, & Ian D. Wilson1
1Imperial College London, London, UK. 2Waters Corporation, Wilmslow, UK. 3 University of Roehampton, London, UK. 4University of North Carolina, Chapel Hill, USA. 5The University of Reading, Reading, UK. 6AstraZeneca, Cambridge, UK.

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Marine Letertre (Presenter) Imperial College London

Presenter Bio: I am a third year PhD student within the division of Integrative Systems Medicine and Digestive Disease at Imperial College London, studying the interactions between the gut microbiota and drug metabolism. I am mainly using targeted and untargeted LCMS as well as NMR metabolic profiling and amplicon sequencing. In 2015, I obtained my Master’s Degree specialized in the use of Natural Active Ingredients for pharmaceutical applications (Nantes, France). I have always worked at the interface of Chemistry and Biology and in interdisciplinary projects. It allowed me to take part on diverse studies such as understanding the toxicity of Bisphenol A on human testicular explants using MALDI-Imaging Mass Spectrometry (Rennes, France) or developing a novel class of irreversible kinase inhibitors using organic chemistry technics, enzyme assays and molecular modelling (Auckland, New Zealand).

Relevant Financial Disclosures (within past 24 months) No relevant financial relationship(s) to disclose. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED.

Following several animal experiments which were performed to study drug-microbiome-host interactions and on which we applied pharmaco-metabonomics, a useful tool to patient stratification, we have proved the importance of the gut microbiota in different therapeutic treatment (e.g. methotrexate or paracetamol). However, to limit the animal use and obtain results more robust and representative of human, we are currently developing an in vitro batch culture model, in which faecal homogenates from several human donors are incubated with a specific drug. Preliminary results are promising and show drug- and donor-specific responses over time. Optimization of the assay to apply it clinically is currently on-going.